Sept. 19, 2011 – Center for Drug Evaluation and Research (CDER) Director Janet Woodcock announced in an e-mail to CDER staff that as part of the reorganization of the Office of Medical Policy (OMP) into a Super Office, the former Division of Drug Marketing, Advertising and Communications has been reorganized and elevated into a new Office […]
Read moreTag: DDMAC
DDMACDDMAC Calls Out Recent Marketing Violations in Enforcement Webinar
Sept. 6, 2011 – The FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) issued three Warning Letters and nine Untitled Letters in the past four months, according to DDMAC officials speaking at an Enforcement Webinar held Aug. 25. The Webinar was part of a DDMAC pilot program to allow stakeholders to better understand and learn […]
Read moreDDMAC to Hold Webinar on 2011 Enforcement Actions
Aug. 3, 2011 — The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) announced today that it would hold its second Enforcement Webinar on Thursday, Aug. 25, from 11 AM EST to 11:30 AM EST. “This is a pilot program in which DDMAC will give our stakeholders a chance to directly communicate with the […]
Read moreFDA Declares Victory in Year One of “Bad Ad” Program, But Some Industry Insiders Are Not So Sure
June 14, 2011 — The FDA proclaimed success for the first year of the “Bad Ad” program, through which healthcare professionals are asked to report suspected untruthful or misleading drug promotion to the Division of Drug Marketing, Advertising, and Communications (DDMAC). The program is so successful, says DDMAC leaders, it will be expanded, “based on […]
Read moreMore Social Media Studies Planned at FDA
Immediate Guidance Slips Again May 9, 2011 – A recent notice in the Federal Register calling for comments on a series of Food and Drug Administration (FDA) studies to determine the most effective way of presenting risk information online indicates that the FDA is still a long way from developing significant new social media guidance. This status […]
Read moreFDA to Healthcare Professionals: Help Us Find “Bad Ads”
April 29, 2011 – In a Webinar yesterday, the U.S. Food and Drug Administration’s (FDA’s) Division of Drug Marketing, Advertising, and Communications (DDMAC) reminded medical marketers of its continued actions to enhance surveillance and monitoring of industry marketing by urging physicians and other healthcare professionals to report any potentially misleading marketing activities to DDMAC. Although the year-old program has resulted in only […]
Read moreInnovate with Social Media While Waiting for FDA Guidance, Says Coalition Executive Director
April 11, 2011 – While waiting for the Food and Drug Administration’s (FDA’s) Division of Drug Marketing, Advertising, and Communications (DDMAC) to begin issuing social media guidance, it is important for agencies and clients to create compelling sites for professionals and patients that stay within the FDA’s existing policies, according to John Kamp, executive director […]
Read moreFDA To Hold “Bad Ad” Webinar April 28
April 7, 2011 — The FDA’s Division of Drug Information and its Division of Drug Marketing, Advertising, and Communications are presenting a Webinar April 28 to better inform healthcare professionals about the role they can play in helping the FDA ensure that prescription drug advertising is truthful and not misleading. The Webinar is part of […]
Read moreDDMAC Tells Industry at DIA: “Follow the Regs” Until Social Media Guidance Is Issued
Feb. 28, 2011 — In yet another indication that industry and agencies should not expect major changes in social media marketing rules, Tom Abrams, the head of FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC), told participants at DIA’s annual marketing meeting in Washington, D.C., on Feb. 22 to “follow the regulations” while waiting for formal FDA guidance. During an […]
Read more
General
Coalition Focus for 2011
Coalition Focus for 2011
Although 2011 brings political party shifts in Congress and new challenges, the mission of the Coalition for Healthcare Communication (CHC) remains the same: To protect, for society and individual patients, the benefit of the free flow of healthcare information. This year the CHC will be focusing on four major issues: (1) tax treatment of marketing […]
Read more